Senseonics Announces Pricing of Public Offering of Common Stock
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology
company focused on the development and commercialization of Eversense®,
a long-term, implantable continuous glucose monitoring (CGM) system for
people with diabetes, today announced the pricing of a registered
underwritten public offering of its common stock for proceeds of $130.0
million, before deducting estimated offering expenses payable by
Senseonics. All of the shares sold in the offering were sold by
Senseonics. The offering is expected to close on June 28, 2018, subject
to customary closing conditions. In addition, Senseonics has granted the
underwriter a 30-day option to purchase up to an additional $19.5
million of shares of its common stock.
BTIG, LLC is acting as sole book-running manager for the offering.
A shelf registration statement on Form S-3 relating to the public
offering of the shares of common stock described above was declared
effective by the Securities and Exchange Commission (SEC) on April 19,
2018. Before you invest, you should read the prospectus in the
registration statement and related prospectus supplement that Senseonics
will file with the SEC for more complete information about Senseonics
and this offering. An electronic copy of the prospectus supplement and
accompanying prospectus relating to the offering will be available on
the website of the SEC at www.sec.gov.
Copies of the prospectus supplement, when available, and the
accompanying prospectus relating to the offering may be obtained by
contacting BTIG, LLC, at 825 Third Avenue, 6th Floor, New York, NY,
10022, or by telephone at (212) 593-7555 or by e-mail at [email protected].
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics’ Eversense System is a long-term, implantable device,
which includes a small sensor, smart transmitter and mobile application.
Based on fluorescence sensing technology, the sensor is designed to be
inserted subcutaneously and communicate with the smart transmitter to
wirelessly transmit glucose levels to a mobile device. After insertion,
the sensor is designed to continually and accurately measure glucose
levels. The Eversense System is approved in the United States and
indicated for 90 days of continuous use and the Eversense XL System is
approved in EMEA and indicated for up to 180 days of continuous use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180626005828/en/
INVESTOR:
Senseonics Holdings, Inc.
R. Don Elsey,
301-556-1602
Chief Financial Officer
[email protected]
Source: Senseonics Holdings, Inc.